Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The aim of this study was to investigate the potential association between glaucoma and fecal calprotectin. A total of 144 glaucomatous patients and 66 healthy controls were enlisted for this study. The fecal calprotectin was assessed using enzyme-linked immunosorbent assay. The median fecal calprotectin levels were significantly elevated in glaucoma (73.67 vs 41.97 μg/g; p < 0.001), primary angle-closure glaucoma (76.85 μg/g; p < 0.001) and primary open-angle glaucoma (69.29 μg/g; p = 0.016) groups compared with controls. A notable proportion of the glaucoma (24%; p < 0.001), primary angle-closure glaucoma (21%; p < 0.001) and primary open-angle glaucoma (24%; p < 0.001) subgroups exhibited highly abnormal fecal calprotectin levels (≥250 μg/g). Elevated fecal calprotectin might indicate potential intestinal inflammation in glaucoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/bmm-2023-0352 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Different sources and dosages of zinc oxide and copper influence growth performance and intestinal health of post-weaning piglets.
J Anim Sci
September 2025
Department of Animal Sciences, Laval University, Québec, QC G1V 0A6, Canada.
In pig production, weaning is a critical period where piglets face several environmental stressors. This transition leads to a significant growth reduction and can result in digestive disorders, including diarrhea. To formulate a feed that meets zinc (Zn) and copper (Cu) requirements during the weaning period while minimizing their release into the environment, it became evident that a more bioavailable micro-mineral supplement is necessary.
View Article and Find Full Text PDFAntibodies against integrin αvβ6 have high diagnostic accuracy for ulcerative colitis.
Front Immunol
September 2025
Medicine 1 Unit, Ca' Foncello University Hospital, Treviso, Italy.
Background: Anti-integrin αvβ6 IgG autoantibodies showed good sensitivity and optimal specificity in ulcerative colitis (UC) compared to controls. We aim at confirming the diagnostic accuracy of anti-integrin αvβ6 autoantibodies in an Italian multicentric cohort.
Methods: This observational multicentric study included adult and pediatric patients with inflammatory bowel disease and controls.
Vedolizumab Achieves Pan-Enteric Mucosal Healing in Crohn's Disease: A Prospective Observational Study.
United European Gastroenterol J
September 2025
Sheba Medical Center Tel Hashomer, Faculty of Medical and Health Sciences, Gastroenterology Institute, Tel-Aviv University, Tel Aviv, Israel.
Background: Mucosal healing (MH) is a key treatment goal in Crohn's disease (CD). However, evidence on pan-enteric MH (PE-MH) in CD patients treated with vedolizumab remains limited. We aimed to assess vedolizumab efficacy in achieving PE-MH using PillCam Crohn's capsule.
View Article and Find Full Text PDFWhen to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study.
Inflamm Bowel Dis
September 2025
IBD Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy.
Background: The infliximab (IFX) biosimilar, CT-P13, is available as an intravenous (IV) and subcutaneous (SC) formulation. Although current indications allow the transition from IV CT-P13 to SC CT-P13 after two IV administrations, some clinicians prefer to postpone switching until stable clinical remission has been achieved.
Methods: We evaluate the endoscopic response, treatment persistence, clinical remission, endoscopic remission, and safety profile after one year of treatment with IFX in patients switched from IV to SC after 6 weeks (early switch group) or after 6 months (late switch group).
[Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)].
Bull Cancer
September 2025
Service d'hématologie, département d'oncologie, hôpitaux universitaire de Genève (HUG), faculté de médecine, université de Genève, Genève, Suisse. Electronic address:
Acute graft-versus-host disease (GVHDa) is one of the leading causes of morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT) patients. While the first-line consensus treatment has been based on systemic corticosteroid therapy for many years, ruxolitinib has recently been approved and has become the standard second-line treatment. Nevertheless, the effectiveness of ruxolitinib remains limited to 40 % of cortico-resistant patients, raising the crucial question of selecting a third-line treatment.
View Article and Find Full Text PDF